The China International Import Expo, as an important platform for global trade, provides healthcare companies with the valuable opportunity of showcasing their achievements and engaging in more open and deeper collaboration with partners for broader market opportunities, said business executives.

They made the remarks as the seventh edition of the international exchange platform, which closed on Sunday, attracted many leading pharmaceutical and medical device companies to participate, launching an increasing number of innovative health technologies, products and services for the first time in China.

Lundbeck, a Danish pharmaceutical company that solely focuses on neuroscience, participated in the CIIE for the first time this year.

"CIIE, initiated by China and shared globally, is attracting an increasing number of multinational companies due to its significant 'spillover effect'. As a new friend participant, we at Lundbeck have showcased our 70-year dedication to neuroscience, highlighting our transformative treatments for brain diseases and our achievements in China," said Jens Hoeyer, managing director of Lundbeck for the Chinese mainland and Hong Kong.

"We aim to leverage the CIIE platform to accelerate the introduction of our global innovations into China and expand cooperation with local brain health stakeholders. Together, we are having a positive impact on patients with migraine, depression and other brain diseases, their caregivers and society, contributing to the 'Healthy China 2030' initiative".

At CIIE, Lundbeck showcased its dedication and innovative progress in the field of neuroscience, as well as the milestones of expansion into neuro-rare and neuro-specialty areas, to develop transformative treatments for more patients with brain disorders.

The US-based pharmaceutical company Organon aimed to leverage this year's CIIE to further explore women's reproductive health innovations, addressing the evolving needs of Chinese families, and showcasing its collaborations with local partners.

"Organon's presence at the CIIE this year was centered around critical health challenges that are impacting societies in a multi-dimensional way. Shifts in population structure affect us all, and our commitment is clear: to advance innovative solutions that support fertility and tackle broader women's and families' health challenges," said Zafer Unluer, president of Organon China. "Through the CIIE platform, we aim to accelerate global innovations in China and also bring Chinese innovations into the world. We're dedicated to creating solutions that take root and make a lasting difference, for China and beyond."

The company brought its full spectrum of reproductive health solutions to the expo, including assisted reproductive solutions, long-acting reversible contraceptives, and product pipelines for conditions such as endometriosis, intrauterine adhesions, vaginitis, preeclampsia and menopause.

Incaier, the healthcare arm of Haier Group, has participated in the expo for five consecutive years. This year, more than 50 percent of its products and solutions were showcased for the first time, including over 40 innovative products and solutions, setting a record for the company.

For instance, the company debuted its "intravascular targeted temperature management system "prototype, which is being developed in collaboration with Capital Medical University. This innovation is expected to have a profound impact on the treatment of strokes.

During the expo, Incaier hosted more than 10 events, including the release of the results of a district-level medical community informatization project in Shigatse, Xizang autonomous region, and a forum on the development and clinical application of blood products, seeking more collaboration opportunities with global partners on innovation.

Dong Yilang contributed to this story.